UbiVac opens clinical trial for advanced lung cancer patients


June 3, 2016

Contact: Patricia Pearson, ppearson@the3wgroup.com   503.887.1871

UbiVac , www.ubivac.com, a private, clinical-stage, immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announces the opening of a randomized, clinical trial for patients with definitively treated, stage III, non-small cell lung cancer (NSCLC).

According to UbiVac CEO Dr. Bernard A. Fox, PhD,  “This is a combination vaccine involving our biologic DRibble™ vaccine technology DPV-001, administered with drug formulations Cyclophosphamide, granulocyte-macrophage colony-stimulating factor (GM-CSF) or Imiquimod.”  The optimal selection will depend on the particular characteristics of each patient’s cancer.

Additional details can be found online at clinical trials.gov.

About UbiVac

UbiVac is a clinical stage immuno-oncology company engaged in research and development of therapeutic immunotherapies to combat cancer. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with other research partners. The company’s co-founder, president and CEO, Bernard A. Fox, PhD, holds the Harder Family Endowed Chair for Cancer Research and is member and Chief, Laboratory of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.

Bernie Fox